Expanded HCT-CI Definitions Capture Comorbidity Better for Younger Patients of Allogeneic HCT for Nonmalignant Diseases

By sjmartinez • February 14, 2023

Broglie L, Friend BD, Chhabra S, Logan BR, Bupp C, Schiller G, Savani BN, Stadtmauer E, Abraham AA, Aljurf M, Badawy SM, Perez MAD, Guinan EC, Hashem H, Krem MM, Lazarus HM, Rotz SJ, Wirk B, Yared JA, Pasquini M, Thakar MS, Sorror ML. Expanded HCT-CI Definitions Capture Comorbidity Better for Younger Patients of Allogeneic HCT for Nonmalignant Diseases. Transplant Cell Ther. 2023 Feb;29(2):125.e1-125.e9. doi: 10.1016/j.jtct.2022.11.020. Epub 2022 Nov 25. PMID: 36442768; PMCID: PMC9911359.

Tags: Allogeneic hematopoietic cell transplantation, comorbidities, HCT-CI, Hematology/Oncology, Nonmalignant diseases, Pediatric adolescents and young adults (AYA), Publications

Related Posts

Feasibility of cognitive testing and ecological momentary assessments using smartphones in middle aged and older adults with insomnia

Ghadimi S, Ereso J, Kaula AJ, Taptiklis N, Cormack F, Alessi C, Martin JL, Dzierzewski JM, Naeim A, Kremen S, Te T, Fung CH. Feasibility[...]

A phase 2 trial of niraparib plus bevacizumab maintenance therapy following first-line platinum-based chemotherapy with bevacizumab in advanced ovarian cancer: final analysis and overall survival results from OVARIO

Hardesty MM, Krivak TC, Wright GS, Hamilton E, Fleming EL, Belotte J, Gorman S, Compton N, Clements A, Gray HJ, Konecny GE, Moore RG, Richardson[...]

A phase 1 safety and feasibility trial of a ketogenic diet plus standard of care for patients with recently diagnosed glioblastoma

Amaral LJ, Gresham G, Kim S, Tighiouart M, Nelson TA, Welborn A, Lockshon L, Noorvash B, Rudnick JD, Irwin SA, Freedland SJ, Hu J. A[...]